Racial Differences in Blood Pressure Control from Users of Antihypertensive Monotherapy: Results from the ELSA-Brasil Study

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSOUSA, Camila Tavares
dc.contributor.authorRIBEIRO, Antonio
dc.contributor.authorBARRETO, Sandhi Maria
dc.contributor.authorGIATTI, Luana
dc.contributor.authorBRANT, Luisa
dc.contributor.authorLOTUFO, Paulo
dc.contributor.authorCHOR, Dora
dc.contributor.authorLOPES, Antonio Alberto
dc.contributor.authorMENGUE, Sotero Serrate
dc.contributor.authorBALDONI, Andre Oliveira
dc.contributor.authorFIGUEIREDO, Roberta Carvalho
dc.date.accessioned2022-08-12T17:03:50Z
dc.date.available2022-08-12T17:03:50Z
dc.date.issued2022
dc.description.abstractBackground: It seems that the worst response to some classes of antihypertensive drugs, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, on the part of the Black population, would at least partially explain the worse control of hypertension among these individuals. However, most of the evidence comes from American studies. Objectives: This study aims to investigate the association between self-reported race/skin color and BP control in participants of the Longitudinal Study of Adult Health (ELSA-Brasil), using different classes of antihypertensive drugs in monotherapy. Methods: The study involved a cross-sectional analysis, carried out with participants from the baseline of ELSA-Brasil. Blood pressure control was the response variable, participants with BP values >= 140/90 mmHg were considered out of control in relation to blood pressure levels. Race/skin color was self-reported (White, Brown, Black). All participants were asked about the continuous use of medication. Association between BP control and race/skin color was estimated through logistic regression. The level of significance adopted in this study was of 5%. Results: Of the total of 1,795 users of antihypertensive drugs in monotherapy at baseline, 55.5% declared themselves White, 27.9% Brown, and 16.7% Black. Even after adjusting for confounding variables, Blacks using angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blocker (ARB), thiazide diuretics (thiazide DIU), and betablockers (BB) in monotherapy had worse blood pressure control compared to Whites. Conclusions: Our results suggest that in this sample of Brazilian adults using antihypertensive drugs in monotherapy, the differences in blood pressure control between different racial groups are not explained by the possible lower effectiveness of ACEIs and ARBs in Black individuals.eng
dc.description.abstractFundamento: Aparentemente, a pior resposta a algumas classes de anti-hipertensivos, especialmente inibidores da enzima conversora da angiotensina e bloqueadores de receptor de angiotensina, pela população negra, explicaria, pelo menos parcialmente, o pior controle da hipertensão entre esses indivíduos. Entretanto, a maioria das evidências vêm de estudos norte-americanos. Objetivos: Este estudo tem o objetivo de investigar a associação entre raça/cor da pele autorrelatadas e controle de PA em participantes do Estudo Longitudinal de Saúde do Adulto (ELSA-Brasil) utilizando várias classes de anti-hipertensivos em monoterapia. Métodos: O estudo envolveu uma análise transversal, realizada com participantes da linha de base do ELSA-Brasil. O controle de pressão arterial foi a variável de resposta, participantes com valores de PA ≥140/90 mmHg foram considerados descontrolados em relação aos níveis de pressão arterial. A raça/cor da pele foi autorrelatada (branco, pardo, negro). Todos os participantes tiveram que responder perguntas sobre uso contínuo de medicamentos. A associação entre o controle de PA e raça/cor da pele foi estimada por regressão logística. O nível de significância adotado nesse estudo foi de 5%. Resultados: Do total de 1.795 usuários de anti-hipertensivos em monoterapia na linha de base, 55,5% se declararam brancos, 27,9%, pardos e 16,7%, negros. Mesmo depois de padronizar em relação a variáveis de confusão, negros em uso de inibidores da enzima conversora de angiotensina (IECA), bloqueadores de receptor de angiotensina (BRA), diuréticos tiazídicos (DIU tiazídicos) e betabloqueadores (BB) in monoterapia tinham controle de pressão arterial pior em comparação a brancos. Conclusões: Os resultados deste estudo sugerem que, nesta amostra de brasileiros adultos utilizando anti-hipertensivos em monoterapia, as diferenças de controle de pressão arterial entre os vários grupos raciais não são explicadas pela possível eficácia mais baixa dos IECA e BRA em indivíduos negros.
dc.description.indexMEDLINEeng
dc.description.sponsorshipBrazilian Ministry of Health (Department of Science and Technology)
dc.description.sponsorshipBrazilian Ministry of Science, Technology and Innovation (Financiadora de Estudos e Projetos, FINEP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq [01 06 0010.00, 01 06 0212.00, 01 06 0300.00, 01 06 0278.00, 01 06 0115.00, 01 06 0071.00]
dc.description.sponsorshipFAPEMIG
dc.description.sponsorshipresearch agency of the State of Minas Gerais, Brazil
dc.description.sponsorshipCNPq [310679/2016-8, 465518/2014-1, 300159/99-4, 303371/2014-5]
dc.description.sponsorshipFAPEMIG (Programa Pesquisador Mineiro) [303371/2014-5, PPM-00428-17]
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) [E26/201220/2014]
dc.description.sponsorshipCoordination for the Improvement of Higher Education Personnel -Brazil (CAPES) [001]
dc.identifier.citationARQUIVOS BRASILEIROS DE CARDIOLOGIA, v.118, n.3, p.614-622, 2022
dc.identifier.doi10.36660/abc.20201180
dc.identifier.issn0066-782X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/48307
dc.language.isoeng
dc.language.isopor
dc.publisherARQUIVOS BRASILEIROS CARDIOLOGIAeng
dc.relation.ispartofArquivos Brasileiros de Cardiologia
dc.rightsopenAccesseng
dc.rights.holderCopyright ARQUIVOS BRASILEIROS CARDIOLOGIAeng
dc.subjectAntihypertensive Agentseng
dc.subjectHypertensioneng
dc.subjectContinental Population Groupseng
dc.subjectAnti-Hipertensivos
dc.subjectHipertensão
dc.subjectGrupos de Populações Continentais
dc.subject.otherconverting enzyme-inhibitorseng
dc.subject.otherhypertension prevalenceeng
dc.subject.otherkidney-diseaseeng
dc.subject.otherblackeng
dc.subject.otheroutcomeseng
dc.subject.otherhydrochlorothiazideeng
dc.subject.otheramlodipineeng
dc.subject.otherhealtheng
dc.subject.wosCardiac & Cardiovascular Systemseng
dc.titleRacial Differences in Blood Pressure Control from Users of Antihypertensive Monotherapy: Results from the ELSA-Brasil Studyeng
dc.title.alternativeDiferenças Raciais no Controle da Pressão Arterial em Usuários de Anti-Hipertensivos em Monoterapia: Resultados do Estudo ELSA-Brasil
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalSOUSA, Camila Tavares:Univ Fed Sao Joao Del Rei, Campus Ctr Oeste Dona Lindu, BR-35501296 Divinopolis, MG, Brazil
hcfmusp.author.externalRIBEIRO, Antonio:Univ Fed Minas Gerais, Fac Med & Hosp Clin, Belo Horizonte, MG, Brazil
hcfmusp.author.externalBARRETO, Sandhi Maria:Univ Fed Minas Gerais, Fac Med & Hosp Clin, Belo Horizonte, MG, Brazil
hcfmusp.author.externalGIATTI, Luana:Univ Fed Minas Gerais, Med Prevent & Social, Belo Horizonte, MG, Brazil
hcfmusp.author.externalBRANT, Luisa:Univ Fed Minas Gerais, Fac Med & Hosp Clin, Belo Horizonte, MG, Brazil
hcfmusp.author.externalCHOR, Dora:Escola Saude Publ, Fundacao Oswaldo Cruz, Rio De Janeiro, RJ, Brazil
hcfmusp.author.externalLOPES, Antonio Alberto:Univ Fed Bahia, Fac Med, Salvador, BA, Brazil
hcfmusp.author.externalMENGUE, Sotero Serrate:Univ Fed Ciencias Saude Porto Alegre, Programa Posgrad Epidemiol, Porto Alegre, RS, Brazil
hcfmusp.author.externalBALDONI, Andre Oliveira:Univ Fed Sao Joao Del Rei, Campus Ctr Oeste Dona Lindu, BR-35501296 Divinopolis, MG, Brazil
hcfmusp.author.externalFIGUEIREDO, Roberta Carvalho:Univ Fed Sao Joao Del Rei, Campus Ctr Oeste Dona Lindu, BR-35501296 Divinopolis, MG, Brazil
hcfmusp.citation.scopus2
hcfmusp.contributor.author-fmusphcPAULO ANDRADE LOTUFO
hcfmusp.description.beginpage614
hcfmusp.description.endpage622
hcfmusp.description.issue3
hcfmusp.description.volume118
hcfmusp.origemWOS
hcfmusp.origem.pubmed35319612
hcfmusp.origem.scieloSCIELO:S0066-782X2022000300614
hcfmusp.origem.scopus2-s2.0-85126831798
hcfmusp.origem.wosWOS:000791209200012
hcfmusp.publisher.cityRIO DE JANEIROeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceAmer Diabet Assoc, 2008, DIABETES CARE, V31, pS12, DOI 10.2337/dc08-S012eng
hcfmusp.relation.referenceAquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294eng
hcfmusp.relation.referenceBaldo MP, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005477eng
hcfmusp.relation.referenceBangalore S, 2015, AM J MED, V128, P1195, DOI 10.1016/j.amjmed.2015.04.034eng
hcfmusp.relation.referenceBarber S, 2018, SOC SCI MED, V199, P67, DOI 10.1016/j.socscimed.2017.05.047eng
hcfmusp.relation.referenceBosworth HB, 2002, J NATL MED ASSOC, V94, P236eng
hcfmusp.relation.referenceBrondolo E, 2011, AM J HYPERTENS, V24, P518, DOI 10.1038/ajh.2011.9eng
hcfmusp.relation.referenceChobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2eng
hcfmusp.relation.referenceChor D., 2013, REV SAUDE PUBL, V47, P27, DOI 10.1590/S0034-8910.2013047003835eng
hcfmusp.relation.referenceChor D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216653eng
hcfmusp.relation.referenceChor D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127382eng
hcfmusp.relation.referenceElliott WJ, 1996, CLIN PHARMACOL THER, V60, P582, DOI 10.1016/S0009-9236(96)90155-1eng
hcfmusp.relation.referenceFALKNER B, 1990, HYPERTENSION, V15, P36, DOI 10.1161/01.HYP.15.1.36eng
hcfmusp.relation.referenceFlack JM, 2010, HYPERTENSION, V56, P780, DOI 10.1161/HYPERTENSIONAHA.110.152892eng
hcfmusp.relation.referenceFurberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981eng
hcfmusp.relation.referenceGu A, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003166eng
hcfmusp.relation.referenceHelmer A, 2018, ANN PHARMACOTHER, V52, P1143, DOI 10.1177/1060028018779082eng
hcfmusp.relation.referenceJamerson K, 2008, NEW ENGL J MED, V359, P2417, DOI 10.1056/NEJMoa0806182eng
hcfmusp.relation.referenceJames PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427eng
hcfmusp.relation.referenceJulius S, 2004, J AM COLL CARDIOL, V43, P1047, DOI 10.1016/j.jacc.2003.11.029eng
hcfmusp.relation.referenceMartins D, 2012, CLEV CLIN J MED, V79, P726, DOI 10.3949/ccjm.79a.11109eng
hcfmusp.relation.referenceMengue SS, 2016, REV SAUDE PUBL, V50, DOI [10.1590/S1518-8787.2016050006154, 10.1590/s1518-8787.2016050006154]eng
hcfmusp.relation.referenceMIDDLEMOST SJ, 1994, AM J CARDIOL, V73, P1092, DOI 10.1016/0002-9149(94)90289-5eng
hcfmusp.relation.referenceMill JG, 2013, REV SAUDE PUBL, V47, P54, DOI 10.1590/S0034-8910.2013047003851eng
hcfmusp.relation.referenceMorenoff JD, 2007, SOC SCI MED, V65, P1853, DOI 10.1016/j.socscimed.2007.05.038eng
hcfmusp.relation.referenceMujahid MS, 2011, AM J HYPERTENS, V24, P187, DOI 10.1038/ajh.2010.200eng
hcfmusp.relation.referenceOgedegbe G, 2015, J AM COLL CARDIOL, V66, P1224, DOI 10.1016/j.jacc.2015.07.021eng
hcfmusp.relation.referenceOrtega LM, 2015, NEFROLOGIA, V35, P139, DOI 10.1016/j.nefro.2015.05.014eng
hcfmusp.relation.referencePalla M, 2017, J CLIN HYPERTENS, V19, P344, DOI 10.1111/jch.12867eng
hcfmusp.relation.referencePeck RN, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-201eng
hcfmusp.relation.referencePena SDJ, 2000, RETRATO MOL BRASILeng
hcfmusp.relation.referenceSAUNDERS E, 1990, ARCH INTERN MED, V150, P1707, DOI 10.1001/archinte.150.8.1707eng
hcfmusp.relation.referenceSchmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027eng
hcfmusp.relation.referenceBarroso WKS, 2021, ARQ BRAS CARDIOL, V116, P516, DOI 10.36660/abc.20201238eng
hcfmusp.relation.referenceSuarez-Kurtz G, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00191eng
hcfmusp.relation.referenceWEIR MR, 1995, HYPERTENSION, V26, P124, DOI 10.1161/01.HYP.26.1.124eng
hcfmusp.relation.referenceWhelton PK, 2018, CIRCULATION, V138, pE484, DOI 10.1161/CIR.0000000000000596eng
hcfmusp.relation.referenceWilliams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339eng
hcfmusp.relation.referenceWorld Health Organization, 2004, GLOBAL STATUS REPORTeng
hcfmusp.relation.referenceWright JT, 2005, JAMA-J AM MED ASSOC, V293, P1595, DOI 10.1001/jama.293.13.1595eng
hcfmusp.relation.referenceWright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationcb0c8dbb-6df5-4294-8d8e-e96645a3cec1
relation.isAuthorOfPublication.latestForDiscoverycb0c8dbb-6df5-4294-8d8e-e96645a3cec1
Arquivos
Pacote Original
Agora exibindo 1 - 2 de 2
Imagem de Miniatura
Nome:
art_SOUSA_Racial_Differences_in_Blood_Pressure_Control_from_Users_2022_eng.PDF
Tamanho:
329.98 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Imagem de Miniatura
Nome:
art_SOUSA_Racial_Differences_in_Blood_Pressure_Control_from_Users_2022_por.PDF
Tamanho:
365.28 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (Portuguese)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20